Evidence map›Paper›PMID 33793804›Full record

ArticleThe Journal of pharmacy and pharmacology2021

Oral drug delivery systems using core-shell structure additive manufacturing technologies: a proof-of-concept study.

Jiaxiang Zhang, Pengchong Xu, Anh Q Vo, Michael A Repka

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacy and pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jiaxiang ZhangDepartment of Pharmaceutics and Drug Delivery, The University of Mississippi, University, MS, USA.
Pengchong XuDepartment of Pharmaceutics and Drug Delivery, The University of Mississippi, University, MS, USA.
Anh Q VoDepartment of Pharmaceutics and Drug Delivery, The University of Mississippi, University, MS, USA.
Michael A RepkaDepartment of Pharmaceutics and Drug Delivery, The University of Mississippi, University, MS, USA.
University of Mississippi · US

Funding

Center of Research Excellence in Natural Products Neuroscience (CORE-NPN)P20GM104932 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI MAJUMDAR, SOUMYAJIT · 2012 to 2016
$10.0M
NIGMS NIH HHS P20 GM104932
6 · The paper itself

Abstract

objectivesThe aim of this study was to couple fused deposition modelling 3D printing with melt extrusion technology to produce core-shell-structured controlled-release tablets with dual-mechanism drug-release performance in a simulated intestinal fluid medium. Coupling abovementioned technologies for personalized drug delivery can improve access to complex dosage formulations at a reasonable cost. Compared with traditional pharmaceutical manufacturing, this should facilitate the following: (1) the ability to manipulate drug release by adjusting structures, (2) enhanced solubility and bioavailability of poorly water-soluble drugs and (3) on-demand production of more complex structured dosages for personalized treatment.

methodsAcetaminophen was the model drug and the extrusion process was evaluated by a series of physicochemical characterizations. The geometries, morphologies, and in vitro drug-release performances were compared between directly compressed and 3D-printed tablets. KEY

findingsInitially, 3D-printed tablets released acetaminophen more rapidly than directly compressed tablets. Drug release became constant and steady after a pre-determined time. Thus, rapid effectiveness was ensured by an initially fast acetaminophen release and an extended therapeutic effect was achieved by stabilizing drug release.

conclusionsThe favourable drug-release profiles of 3D-printed tablets demonstrated the advantage of coupling HME with 3D printing technology to produce personalized dosage formulations.

Indexed as

Drug Delivery SystemsAcetaminophenAdministration, OralDelayed-Action PreparationsDrug LiberationPrinting, Three-DimensionalProof of Concept StudySolubilityTabletsTechnology, PharmaceuticalAcetaminophenDelayed-Action PreparationsTablets3D-printed tabletsacetaminophendrug delivery systemshot melt extrusionoral delivery improvementpatient-focused dosages

Identifiers

PMID33793804
PMCPMC7940344
OpenAlexW3121048914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.